The pathophysiological significance of abdominal fat on the status of GH secretion

The pathophysiological significance of abdominal fat on the status of GH secretion - The pathophysiological significance of abdominal fat on the status of GH secretion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004665

Enrollment

Registered

2010-12-03

Start date

2009-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly, Adult GH deficiency

Interventions

Duration 48 weeks Acromegaly surgery or drug therapy Duration 48 weeks Adult GH deficiency GH replacement therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Acromegaly Patient whom surgery or drug therapy is indicated Adult GH deficiency patient whom GH replacement therapy is Indicated

Exclusion criteria

Exclusion criteria: Acromegaly Patient who is unsuitable for this study (Judged by a doctor) Patient who has malignancy Patient who is pregnant or may get pregnant Adult GH deficiency Patient who is unsuitable for this study (Judged by a doctor) Patient who has malignancy Patient who is pregnant or may get pregnant Patient who has diabetes mellitus

Design outcomes

Primary

Measure	Time frame
the pathophysiological significance of abdominal fat on the status of GH secretion	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026